Clinical trials recruiting in Oshawa, Canada

Phase breakdown

Conditions recruiting in Oshawa, Canada

Recruiting trials in Oshawa, Canada

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
  NCT06227910 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
  NCT06629779 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
  NCT06235697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Duration of Anti-PD-1 Therapy in Metastatic Melanoma
  NCT02821013 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
  NCT07173855 · Phase: Phase 4 · Ages: 16 Years and older · Sex: All (male and female)
• Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
  NCT05753618 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
  NCT04335292 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
  NCT05928039 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
  NCT05592938 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: Female
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
  NCT03573089 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
  NCT07175428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
  NCT07245394 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male

Common questions

How many clinical trials are recruiting in Oshawa, Canada?

32 recruiting trials have at least one study site in Oshawa, Canada.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.